期刊文献+

来那度胺的合成进展

Progress in the Synthesis of Lenalidomide
下载PDF
导出
摘要 来那度胺是一种新型免疫调节剂,本文对来那度胺的合成路线进行了总结,利用不同关键中间体分类对来那度胺的合成路线进行了综述和评价。 Lenalidomide is a new type of immunomodulant. In this article, we conclude its synthetic route, different key intermediate classification was used to review and evaluate its synthetic process.
作者 张程 叶雨婷 Zhang Cheng;Ye Yuting(Nanjing Health School,Nanjing 210000,China)
出处 《广东化工》 CAS 2019年第2期152-153,共2页 Guangdong Chemical Industry
关键词 来那度胺 抗肿瘤药物 骨髓增生异常综合症 合成路线 Lenalidomide antitumor agent Myelin dysplasia synthetic route
  • 相关文献

参考文献8

二级参考文献54

  • 1汤小伟,刘增路,毛振民.沙利度胺及其类似物抗肿瘤作用研究进展[J].中国药房,2006,17(12):944-946. 被引量:6
  • 2宋丽洁,封宇飞,傅得兴,胡欣,王唯红.新型免疫调节药来那度胺的药理及临床研究进展[J].中国新药杂志,2006,15(21):1889-1892. 被引量:14
  • 3严冬翔,刘增路,毛振民.多发性骨髓瘤治疗药物研究进展[J].中国药房,2007,18(2):143-146. 被引量:7
  • 4List AF. Lenalidomide-The phoenix rises [J]. N Engl J ivied, 2007, 357(21): 2183-2186.
  • 5Sorbera LA, Castafier J, Bayes M. CC-5013 [J]. Drugs Future, 2003, 28 (5) : 425-431.
  • 6Muller GW, Chen R, Huang SY, et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-α production [J]. Bioorg Med Chem Lett, 1999, 9 (11) : 1625-1630.
  • 7Muller GW, Chen R, Saindane MT, et al. Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolines: WO, 2006028964 [P]. 2006-03-16. (CA 2006, 144: 292576)
  • 8Soderberg BC, Shriver JA, Wallace JM, et al. Synthesis of indoles by palladium-catalyzed reductive N-heteroannulation of 2-nitrostyrenes: methyl indole-4-carboxylate [J]. Org Synth, 2003, 80: 75-84.
  • 9Abe M, Akiyama T, Umezawa Y, et al. Synthesis and biological activity of sulphostin analogues, novel dipeptidyl peptidase Ⅳ inhibitors [J]. Bioorg Med Chem, 2005, 13 (3) : 785-797.
  • 10Muller GW, Stirling DI, Chen RSC, et al. Substituted 2- (2,6-dioxopiperidin-3-yl)phthalimides and -1 -oxoisoindolines and method of reducing TNF-α levels: WO, 9803502 [P]. 1998-01-29. (CA 1998, 128: 140615)

共引文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部